

**UNITED STATES OF AMERICA
THE FEDERAL TRADE COMMISSION
OFFICE OF ADMINISTRATIVE LAW JUDGES**

In the Matter of

**Caremark Rx, LLC,
Zinc Health Services, LLC,
Express Scripts, Inc.,
Evernorth Health, Inc.,
Medco Health Services, Inc.,
Ascent Health Services LLC,
OptumRx, Inc.,
OptumRx Holdings, LLC,
and
Emisar Pharma Services LLC.**

DOCKET NO. 9437

NOTICE OF WITHDRAWAL OF APPEARANCE

PLEASE TAKE NOTICE that Daria K. Bejan hereby withdraws as attorney of record on behalf of nonparty Sanofi-Aventis U.S. LLC in the above-captioned matter.

Dated: June 2, 2026

Respectfully submitted,

By: /s/Daria K. Bejan

Julie E. McEvoy
Lin W. Kahn
Melissa Lim Patterson
Jones Day
51 Louisiana Avenue, NW
Washington, DC 20001

(202) 879-3939
jmcevoy@jonesday.com
lkahn@jonesday.com
mpatterson@jonesday.com

*Counsel for Nonparty Sanofi-Aventis
U.S. LLC*

CERTIFICATE OF SERVICE

I hereby certify that on the 2nd day of June 2026, I filed the foregoing document electronically using the FTC’s E-Filing System, which will send notification of such filing to:

April Tabor
Secretary
Federal Trade Commission
600 Pennsylvania Ave., NW, Rm H-113
Washington, DC 20580
ElectronicFilings@ftc.gov

The Honorable Jay L. Himes
Office of Administrative Law Judges
Federal Trade Commission
600 Pennsylvania Ave., NW, Rm H-110
Washington, DC 20580
oalj@ftc.gov

I certify that no portion of the filing was drafted by generative artificial intelligence (“AI”) (such as ChatGPT, Microsoft Copilot, Harvey.AI, or Google Gemini). I also certify that I caused the foregoing document to be served via email to:

Rebecca Egeland
Armine Black
Nicholas Leefer
Amanda Triplett
Alpa G. Davis
Andrew Kennedy
Bradley S. Albert
Evan J. Cartagena
Federal Trade Commission
600 Pennsylvania Avenue, NW
Washington, D.C. 20580
regeland@ftc.gov
ablack1@ftc.gov
nleefer@ftc.gov
atriplett@ftc.gov
adavis6@ftc.gov
akennedy1@ftc.gov
balbert@ftc.gov
ecartagena@ftc.gov

Counsel Supporting the Complaint

Kristen C. Limarzi
Connie Lee
Sophia A. Hansell
Stephen Weissman
Michael J. Perry
Matthew S. Rozen
Gibson, Dunn & Crutcher LLP

Ben A. Sherwood
Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, New York 10166
bsherwood@gibsondunn.com

Thomas Tyson

1700 M. St. NW
Washington, DC 20036
klimarzi@gibsondunn.com
clee@gibsondunn.com
shansell@gibsondunn.com
sweissman@gibsondunn.com
mjerry@gibsondunn.com
mrozen@gibsondunn.com

Matthew C. Parrott
Gibson, Dunn & Crutcher LLP
3161 Michelson Drive, Suite 1200
Irvine, CA 92612
mparrott@gibsondunn.com

*Counsel for Respondents OptumRx, Inc.;
OptumRx Holdings, LLC; and
Emisar Pharma Services LLC*

Dated: June 2, 2026

Gibson, Dunn & Crutcher LLP
One Embarcadero Center Suite 2600
San Francisco, California 94111
ttyson@gibsondunn.com

David Reck
Gibson, Dunn & Crutcher LLP
1801 California Street Suite 4200
Denver, CO 80202
dreck@gibsondunn.com

Respectfully submitted,

By: /s/Daria K. Bejan

Julie E. McEvoy
Lin W. Kahn
Melissa Lim Patterson
Jones Day
51 Louisiana Avenue, NW
Washington, DC 20001
(202) 879-3939
jmcevoy@jonesday.com
lkahn@jonesday.com
mpatterson@jonesday.com

Counsel for Sanofi-Aventis U.S. LLC